GlobeNewswire

2018 International Cost Insight Product Cost Management Conference

Dela

Join the most Progressive Companies in the World to Learn How PCM Strategies & Technologies Improve Profitability & Accelerate Design to Delivery Time

CONCORD, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- aPriori, the leading provider of enterprise product cost management software solutions, announces today that the 6th annual Cost Insight International Product Cost Management conference will be held on June 11-13, 2018.

The venue for this year's event is Wentworth by the Sea in New Castle, New Hampshire, located approximately 1 hour from Boston Logan Airport by bus or car.  This event is open to both aPriori customers and representatives from any manufacturers that are interested in learning more about product cost management technology and best practices.

Visit the Cost Insight 2018 Event Website for complete information and register for this year's program.

Why Should You Attend Cost Insight 2018?

As pressure increases to deliver innovative and customized products to market faster, manufacturers are struggling to maintain product profits and accelerate design to delivery schedules.  At Cost Insight 2018, join attendees from leading product manufacturers around the world who will gather to share insights and discover new strategies and tactics in product design, sourcing and quoting to address this complex problem.

  • Learn from the Best
    • The International Cost Insight PCM Conference attracts the largest collection of companies and representatives from around the world who are using advanced product cost management strategies to help meet their business goals.
    • Hear case studies from some of the world's leading global manufacturers including Cisco, General Electric, and Whirlpool where they talk about results and lessons learned along their PCM journey. 
      • What are best practices for arming design engineers with early cost and DFM feedback to reduce churn
      • How companies are taking advantage of data in their digital transformation to generate cost and manufacturability insights to track new product development projects and to optimize designs
      • Where PCM solutions have been applied to change the way manufacturers collaborate with their suppliers
  • Practical Application Workshops
    • After General Sessions in the morning, attendees break into workshop tracks that align with either their role (design/engineering or sourcing/supply chain) or skill level.
    • An "Intro to PCM" track is provided on Day 1 for attendees who are planning to extend or implement product cost management in their product development, sourcing or quoting processes.  This track will include sessions on how to evaluate vendor partners, how to successfully develop a year 1 implementation plan and for folks who have a background in Cost Engineering, how to expand your reach by leveraging people in design/engineering to do early phase costing.
  • See the Latest PCM Technology Breakthroughs
    • Leaders of the aPriori product management team will talk about key breakthroughs and new capabilities that are going to be delivered in future releases of the product. 
    • New at this year's conference is an Advanced Technology Showcase - in an exhibition style setting, aPriori engineers will demonstrate the most exciting technology breakthroughs covering a variety of different use cases across aPriori's key industries of Aerospace & Defense, Automotive, Industrial Machinery and High Tech Electronic Equipment.

Who Should Attend?

Product Designers & Engineers If you have anything to do with designing or engineering a discrete manufactured product, and want to learn how to use cost and DFM data to optimize designs, and how to avoid subtle errors that increase manufacturing cost, and result in mind numbing ECOs.  you should join us at Cost Insight to learn how Design to Cost and Design for Manufacturability capabilities can help you innovate and eliminate  wasteful exercises.
Sourcing, Buyers, Supply Chain If you have anything to do with sourcing or buying engineered components or assemblies that become part of your finished product, and you're struggling to find new ways to squeeze cost out of these purchased parts..  you should join us at Cost Insight to learn how our should costing capabilities provide cost and manufacturing details the can help with vendor selection and negotiations and how our, bulk costing & analytics can help you quickly spot where you may be getting overcharged.
Design & Sourcing Team Management If you are managing a team that is responsible for product design or sourcing, and you are being asked by your senior executives to report on the forecast cost of the product throughout the design cycle.   you should join us at Cost Insight to learn how your team can leverage product cost estimation capabilities in aPriori to stay on track and design products to cost.
Cost Estimating Professionals If you're a professional cost estimator, working in either a big OEM or a mid-size supplier, and you simply can't keep up with the volume of costing requests.  you should join us at Cost Insight learn how aPriori can dramatically accelerate the process and help you provide DFM guidance to improve the value of customer's products

For More Information on Cost Insight 2018

For complete information and to register for the event, please visit the Cost Insight 2018 website

You can also follow the latest event updates on Twitter and LinkedIn.  Search for our event hashtag #CostInsight.

Interested individuals can also send an email to Rick Burke, aPriori Vice President of Marketing, at rburke@apriori.com or call +1-978-451-7675.

About aPriori
aPriori software and services generate hard-dollar product cost savings for discrete manufacturing and product innovation companies. Using aPriori's real-time product cost assessments, employees in engineering, sourcing and manufacturing make more-informed decisions that drive costs out of products pre- and post-production. With aPriori, manufacturers launch products at cost targets, maximize savings in re-work projects and avoid overpaying for sourced parts.  To learn more about aPriori and its product cost management solutions and services, visit www.apriori.com or call 1.978.371.2006. To see an overview demonstration of aPriori, click here.

aPriori on Twitter @aPriori_Inc.
aPriori on LinkedIn Product Costing Blog

aPriori and aPriori Technologies are registered trademarks of aPriori Technologies Inc. All other trademarks, registered trademarks or service marks belong to their respective holders.

CONTACT:
Rick Burke
Vice President, Marketing
rburke@apriori.com
978.451.7675




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aPriori Technologies via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum